Use of COVID-19 Vaccines in the United States
Interim Clinical Considerations
Summary of recent changes (last updated February 22, 2022):
- Added considerations for an 8-week interval between the first and second doses of a primary mRNA vaccine schedule
Get Email Updates
Receive email updates about this page.
COVID-19 Vaccines, Recommendations, and Schedule
Special Situations and Populations
Appendices
- People who received COVID-19 vaccine outside the United States (Appendix A)
- People who received COVID-19 vaccine as part of a clinical trial (Appendix B)
- Vaccine administration errors and deviations (Appendix C)
- Guidance for people who are moderately or severely immunocompromised and vaccinated with Janssen COVID-19 vaccine (Appendix D)
- Triage of people with a history of allergies or allergic reactions (Appendix E)
- Ingredients included in COVID-19 vaccines (Appendix F)
Page last reviewed: March 15, 2022
Content source: National Center for Immunization and Respiratory Diseases